Streetbeat News

TDSGF

Telo Genomics Corp

http://www.3dsignatures.com/

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

Open

0.08

Mkt cap

5.6M

Volume

28K

High

0.08

P/E Ratio

-2.50

52-wk high

0.19

Low

0.07

Div yield

N/A

52-wk low

0.07

Telo Genomics Corp. has successfully closed an oversubscribed private placement, raising $2.5 million through the sale of 25,459,000 units at $0.10 each. Each unit includes one common share and one non-transferable warrant.

Portfolio Pulse from

December 23, 2024 | 9:15 pm

Telo Genomics Corp. has received approval from the Intellectual Property Ontario Program, which will help the company expand its intellectual property portfolio. This approval is significant for Telo's telomere technology platform in oncology.

Portfolio Pulse from

November 19, 2024 | 2:00 pm

Telo Genomics Corp (OTC:TDSGF) announced that its prognostic test for smoldering multiple myeloma, TeloViewSMM, has been accepted for publication in the American Journal of Hematology. The test demonstrated superior performance in predicting disease progression and stability compared to other oncology tests. The company recently announced a private placement to raise $2 million.

Portfolio Pulse from Vandana Singh

May 30, 2024 | 12:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.